Iga Nephropathy (Berger's Disease) - Multiple Locations in the US (Clinical Trial 45704)

Scroll down to search for clinics conducting this clinical trial.

Study summary

The ALIGN Study for IgA Nephropathy

The ALIGN Study is testing an investigational medication, called atrasentan, that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with IgA nephropathy. If you have IgAN this study may be an option for you.

Who can be in the study?
You may qualify to participate if you:

Are 18 years of age or older
Have been diagnosed with IgAN from a biopsy
Are taking a stable dose of a medication called an ACE inhibitor or ARB or are unable to tolerate ACEi/ARB medication
Have elevated levels of protein in your urine
Do not have severe loss of kidney function
Are willing to use adequate contraception

Ask your doctor about these eligibility criteria and if you may qualify.If you want more information about the ALIGN study and to see whether you are eligible to participate in this clinical trial, please CLICK HERE.

Study is available at

This study is being conducted NATIONWIDE! To find clinics conducting this study near you please use search feature below.

Study Locations

24 study locations found: Filter Results

Services for Research Sites

Services for CROs and Sponsors

Services for Other Recruiters

Study summary

Study is available at

Study Locations

Latest Blog Posts

Useful Links

Contact Us